Ocugen stock up 16% premarket after company announced positive results for its COVID vaccine

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

Ocugen Inc. stock rallied 16% in premarket trade Monday, after the biopharma company announced positive results in a trial of its COVID vaccine Covaxin. The...

Ocugen Inc. stock OCGN rallied 16% in premarket trade Monday, after the biopharma company announced positive results in a trial of its COVID vaccine Covaxin. The Phase 2/3 trial involved 491 U.S. adult participants who receive two doses of Covaxin or placebo 28 days apart. Covaxin is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.

adult participants who receive two doses of Covaxin or placebo 28 days apart. Covaxin is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Pdr_US 🫡

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines